Omeros OMS302 Drug for Maintaining Pupil Dilation in Cataract Surgery Sees Positive Results in Clinical Trial
March 24, 2011
Omeros Corporation today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros’ proprietary PharmacoSurgery(TM) product in development to maintain intra-operative mydriasis (pupil dilation) and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.
In this 221-patient Phase 2b clinical study, subjects treated with OMS302 demonstrated statistically significant and clinically meaningful maintenance of mydriasis throughout the cataract procedure. If mydriasis is not maintained throughout the procedure, the risk of injuring structures within the eye increases and the required operating time is often prolonged. Of equal clinical relevance, OMS302 also significantly decreased pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). The drug product was safe and well tolerated in this study.
Click here to read the full release.
Comments
Jump down to form below to submit your own comments
